A NEW non-stimulant medication – Atomoxetine HCI – is now available in Malaysia, offering children and adults suffering from Attention Deficit Hyperactive Disorder (ADHD), a safer and more effective treatment option. It’s the first and only non-stimulant approved for treatment of ADHD in children, adolescents and adults.
ADHD is a neurobiological condition affecting 3 - 7% of school-aged children, roughly two children in every classroom. Based on the 2001 census and 2nd National Health and Morbidity Survey held in 1996, about 330,000 Malaysian children, or 4.3%, are suffering from ADHD. Research has also shown that a number of children suffering from ADHD go on to be adults with ADHD.
